Summit To Present Phase 2 Codify Trial Data Highlighting Ridinilazole’


Sign up online today & collaborate

or click here to find out more

Summit To Present Phase 2 Codify Trial Data Highlighting Ridinilazole’s Preservation Of The Microbiome In CDI Patients At ASM Microbe 2016


Oxford, UK – Summit Therapeutics plc, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection (‘CDI’), announces that the Company will present additional positive Phase 2 CoDIFy trial data on ridinilazole versus standard of care, vancomycin, highlighting ridinilazole’s preservation of the microbiome in the treatment of CDI. These data will be presented as posters at the ASM Microbe 2016 meeting that will be held 16-20 June in Boston, MA, US.

Ridinilazole is part of a novel structural class of antibiotics with potential for broad use in the treatment of CDI. As previously reported, in a Phase 2 clinical trial called CoDIFy, ridinilazole demonstrated substantial clinical benefit over vancomycin. The data to be presented at ASM Microbe, including additional results from CoDIFy, further highlight ridinilazole as a highly selective antibiotic for CDI with the potential to treat the initial infection and reduce recurrent disease, the key clinical issue in the treatment of CDI.

All of the poster presentations take place on 20 June 2016 from 12:30-14:30 EDT.

CompanySummit plc
Company Website

© Catalyst Innovation Portal 2019